SDB-005 is an indazole-based synthetic cannabinoid designer drug. It is presumed to be an agonist of the CB1 and CB2 cannabinoid receptors. SDB-005 is the indazole core analogue of PB-22 where the 8-hydroxyquinoline has also been replaced with a naphthalene group.
Cas No:
Formula: C23H22N2O2
IUPAC:
Appearance:
Purity: 99.99%